Adjuvant trastuzumab chemotherapy in early breast cancer: meta-analysis of randomised trials and cost-effectiveness analysis.
CONCLUSION: Trastuzumab for HER2-positive early breast cancer had a high ICER. It is unclear why the Pharmaceutical Benefits Scheme listing does not use restrictions to improve the cost-effectiveness of the drug.
PMID: 31104310 [PubMed - in process]
Source: Swiss Medical Weekly - Category: General Medicine Authors: Doan TN, Barendregt J Tags: Swiss Med Wkly Source Type: research
More News: Australia Health | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Disability | General Medicine | HER2 | Herceptin | Study | Switzerland Health | Women